392 related articles for article (PubMed ID: 22403241)
1. Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.
Liu Q; Chen Y; Auger-Messier M; Molkentin JD
Circ Res; 2012 Apr; 110(8):1077-86. PubMed ID: 22403241
[TBL] [Abstract][Full Text] [Related]
2. TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NFκB, and Bnip3 Pathways.
Li L; Chen Y; Li J; Yin H; Guo X; Doan J; Molkentin JD; Liu Q
Sci Rep; 2015 Nov; 5():16626. PubMed ID: 26564789
[TBL] [Abstract][Full Text] [Related]
3. Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.
Luo Y; Jiang N; May HI; Luo X; Ferdous A; Schiattarella GG; Chen G; Li Q; Li C; Rothermel BA; Jiang D; Lavandero S; Gillette TG; Hill JA
Circulation; 2021 Jul; 144(1):34-51. PubMed ID: 33821668
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
[TBL] [Abstract][Full Text] [Related]
5. GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity.
Hullmann JE; Grisanti LA; Makarewich CA; Gao E; Gold JI; Chuprun JK; Tilley DG; Houser SR; Koch WJ
Circ Res; 2014 Dec; 115(12):976-85. PubMed ID: 25332207
[TBL] [Abstract][Full Text] [Related]
6. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
[TBL] [Abstract][Full Text] [Related]
7. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
[TBL] [Abstract][Full Text] [Related]
8. The Ca(v)3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice.
Chiang CS; Huang CH; Chieng H; Chang YT; Chang D; Chen JJ; Chen YC; Chen YH; Shin HS; Campbell KP; Chen CC
Circ Res; 2009 Feb; 104(4):522-30. PubMed ID: 19122177
[TBL] [Abstract][Full Text] [Related]
9. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
[TBL] [Abstract][Full Text] [Related]
10. NULP1 Alleviates Cardiac Hypertrophy by Suppressing NFAT3 Transcriptional Activity.
Zhang X; Lei F; Wang XM; Deng KQ; Ji YX; Zhang Y; Li H; Zhang XD; Lu Z; Zhang P
J Am Heart Assoc; 2020 Aug; 9(16):e016419. PubMed ID: 32805187
[TBL] [Abstract][Full Text] [Related]
11. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.
Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM
J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543
[TBL] [Abstract][Full Text] [Related]
12. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
[TBL] [Abstract][Full Text] [Related]
13. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy.
Facundo HT; Brainard RE; Watson LJ; Ngoh GA; Hamid T; Prabhu SD; Jones SP
Am J Physiol Heart Circ Physiol; 2012 May; 302(10):H2122-30. PubMed ID: 22408028
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes.
Fiedler B; Lohmann SM; Smolenski A; Linnemuller S; Pieske B; Schroder F; Molkentin JD; Drexler H; Wollert KC
Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11363-8. PubMed ID: 12177418
[TBL] [Abstract][Full Text] [Related]
15. Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway.
Finsen AV; Lunde IG; Sjaastad I; Østli EK; Lyngra M; Jarstadmarken HO; Hasic A; Nygård S; Wilcox-Adelman SA; Goetinck PF; Lyberg T; Skrbic B; Florholmen G; Tønnessen T; Louch WE; Djurovic S; Carlson CR; Christensen G
PLoS One; 2011; 6(12):e28302. PubMed ID: 22164265
[TBL] [Abstract][Full Text] [Related]
16. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A.
Maejima Y; Usui S; Zhai P; Takamura M; Kaneko S; Zablocki D; Yokota M; Isobe M; Sadoshima J
Circ Heart Fail; 2014 May; 7(3):479-90. PubMed ID: 24526353
[TBL] [Abstract][Full Text] [Related]
17. GSK-3β/NFAT Signaling Is Involved in Testosterone-Induced Cardiac Myocyte Hypertrophy.
Duran J; Oyarce C; Pavez M; Valladares D; Basualto-Alarcon C; Lagos D; Barrientos G; Troncoso MF; Ibarra C; Estrada M
PLoS One; 2016; 11(12):e0168255. PubMed ID: 27977752
[TBL] [Abstract][Full Text] [Related]
18. Cdc42 is an antihypertrophic molecular switch in the mouse heart.
Maillet M; Lynch JM; Sanna B; York AJ; Zheng Y; Molkentin JD
J Clin Invest; 2009 Oct; 119(10):3079-88. PubMed ID: 19741299
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4.
Zou J; Le K; Xu S; Chen J; Liu Z; Chao X; Geng B; Luo J; Zeng S; Ye J; Liu P
Mol Cell Endocrinol; 2013 May; 370(1-2):103-12. PubMed ID: 23518069
[TBL] [Abstract][Full Text] [Related]
20. Cardiac remodeling is not modulated by overexpression of muscle LIM protein (MLP).
Kuhn C; Frank D; Dierck F; Oehl U; Krebs J; Will R; Lehmann LH; Backs J; Katus HA; Frey N
Basic Res Cardiol; 2012 May; 107(3):262. PubMed ID: 22421737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
